Krystal Biotech’s (KRYS) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report sent to investors on Thursday,Benzinga reports. Chardan Capital currently has a $212.00 price target on the stock.

Several other brokerages also recently weighed in on KRYS. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, December 10th. Finally, Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Stock Performance

Shares of KRYS opened at $163.64 on Thursday. The company’s 50-day simple moving average is $181.27 and its 200-day simple moving average is $185.06. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The stock has a market capitalization of $4.71 billion, a PE ratio of 92.45 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter last year, the company posted ($0.67) EPS. The firm’s revenue was up 879.9% compared to the same quarter last year. On average, sell-side analysts predict that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the company. EFG Asset Management North America Corp. boosted its position in shares of Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the period. Arizona State Retirement System grew its position in shares of Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after acquiring an additional 108 shares during the last quarter. Fiera Capital Corp increased its holdings in shares of Krystal Biotech by 0.8% in the 2nd quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares during the period. Finally, KBC Group NV raised its position in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after purchasing an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).